Back to Newsroom

Apogenix’ APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma

HEIDELBERG, Germany, Jan. 13, 2014 – Apogenix, a clinical stage biopharmaceutical company, announced today the successful completion of its phase II proof-of-concept trial with APG101 in patients with recurrent glioblastoma. All endpoints of the randomized controlled trial that compared the efficacy and safety of a combination therapy of APG101 and radiotherapy versus radiotherapy alone were achieved or exceeded. During treatment with APG101 for up to two years, no drug-related serious adverse events were observed, underlining the excellent safety profile and very good tolerability of APG101.